Celiac Disease Prevention
Prevention of Celiac Disease in Children at Genetic Risk - Optimized Introduction of Gluten and Follow-up of Immunization
1 other identifier
interventional
168
1 country
1
Brief Summary
Celiac disease is an autoimmune disease induced by wheat gluten. Destruction of epithelial cells and microvilli on gut mucosa is causing a "flat mucosa" and an absorption defect. The diagnosis is based on typical microscopical finding in biopsy specimens but serum antibodies to tissue transglutaminase and certain gliadin peptides are strongly associated with the pathology. Severe diarrhoea associated with growth disturbance in infancy was historically characterising the disease but is nowadays rare. Clinically more mild forms including silent disease are very common. Studies based on antibody screening and biopsies done in autoantibody positive subjects have confirmed a frequency of about 1-2% in adult population. Undiagnosed disease is associated with deficiencies of nutrients and vitamins leading to various chronic symptoms like anaemia, osteoporosis and general fatigue. It has also been recently found that undiagnosed celiac disease may be associated with general underachievement in society probably associated with common psychological symptoms like fatigue and depression during the adolescence. The disease is treated by complete elimination of wheat, rye and barley in the diet, which is laborious and causing considerable extra costs in nutrition. Much progress has been recently made in understanding of the genetic background and immune markers associated with the disease as well as in understanding those patterns of gluten introduction in infancy, which might be connected to a high disease risk. Our aim in this study is in the first phase to identify children at high genetic risk (around 10%) and in a follow-up study to define:
- 1.Are the age, dose of gluten and presence of simultaneous breast feeding at the introduction of gluten associated with the risk of celiac disease?
- 2.Is it possible to decrease the frequency of celiac disease by nutritional counselling?
- 3.Is it possible to predict development of celiac disease by immunological tests before the development of mucosal lesion
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2007
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2007
CompletedFirst Submitted
Initial submission to the registry
February 6, 2008
CompletedFirst Posted
Study publicly available on registry
February 18, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2014
CompletedAugust 23, 2013
August 1, 2013
6.8 years
February 6, 2008
August 22, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
development of transglutaminase antibodies
2-4 year age
Secondary Outcomes (2)
gliadin peptide antibodies
2-4 years
mucosal biopsy in TGA positive childre
2-4 years
Study Arms (2)
1
ACTIVE COMPARATOROptimization of gluten introduction by nutritional councelling
2
NO INTERVENTIONNo specific nutritional councelling. Follow-up of gluten introduction
Interventions
Eligibility Criteria
You may qualify if:
- Presence of HLA-risk alleles DQA1\*05 and DQB1\*02
You may not qualify if:
- Lack of these HLA risk alleles
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Kuopio University Hospitallead
- University of Eastern Finlandcollaborator
- University of Turkucollaborator
- Finnish Institute for Health and Welfarecollaborator
- Päivikki and Sakari Sohlberg Foundation, Finlandcollaborator
- Kätilöopisto Maternity Hospitalcollaborator
Study Sites (1)
Kuopio University Hospital
Kuopio, FIN-70211, Finland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jorma Ilonen, MD
University of Eastern Finland
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 6, 2008
First Posted
February 18, 2008
Study Start
October 1, 2007
Primary Completion
August 1, 2014
Study Completion
December 1, 2014
Last Updated
August 23, 2013
Record last verified: 2013-08